BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17482893)

  • 1. Live and let die: in vivo selection of gene-modified hematopoietic stem cells via MGMT-mediated chemoprotection.
    Milsom MD; Williams DA
    DNA Repair (Amst); 2007 Aug; 6(8):1210-21. PubMed ID: 17482893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
    Schambach A; Baum C
    DNA Repair (Amst); 2007 Aug; 6(8):1187-96. PubMed ID: 17482894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O6-methylguanine-DNA-methyltransferase (MGMT) gene therapy targeting haematopoietic stem cells: studies addressing safety issues.
    Sorg UR; Kleff V; Fanaei S; Schumann A; Moellmann M; Opalka B; Thomale J; Moritz T
    DNA Repair (Amst); 2007 Aug; 6(8):1197-209. PubMed ID: 17499560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells.
    Ragg S; Xu-Welliver M; Bailey J; D'Souza M; Cooper R; Chandra S; Seshadri R; Pegg AE; Williams DA
    Cancer Res; 2000 Sep; 60(18):5187-95. PubMed ID: 11016647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal inventory screens uncover monoclonality following serial transplantation of MGMT P140K-transduced stem cells and dose-intense chemotherapy.
    Giordano FA; Sorg UR; Appelt JU; Lachmann N; Bleier S; Roeder I; Kleff V; Flasshove M; Zeller WJ; Allgayer H; von Kalle C; Fruehauf S; Moritz T; Laufs S
    Hum Gene Ther; 2011 Jun; 22(6):697-710. PubMed ID: 21319998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-expression of MGMT(P140K) and alpha-L-iduronidase in primary hepatocytes from mucopolysaccharidosis type I mice enables efficient selection with metabolic correction.
    Wang D; Worsham DN; Pan D
    J Gene Med; 2008 Mar; 10(3):249-59. PubMed ID: 18076130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Trial of MGMT(P140K) Gene Therapy in the Treatment of Pediatric Patients with Brain Tumors.
    Kramer B; Singh R; Wischusen J; Dent R; Rush A; Middlemiss S; Ching YW; Alexander IE; McCowage G
    Hum Gene Ther; 2018 Aug; 29(8):874-885. PubMed ID: 29385852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amelioration of murine beta-thalassemia through drug selection of hematopoietic stem cells transduced with a lentiviral vector encoding both gamma-globin and the MGMT drug-resistance gene.
    Zhao H; Pestina TI; Nasimuzzaman M; Mehta P; Hargrove PW; Persons DA
    Blood; 2009 Jun; 113(23):5747-56. PubMed ID: 19365082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stem cell selection in vivo using foamy vectors cures canine pyruvate kinase deficiency.
    Trobridge GD; Beard BC; Wu RA; Ironside C; Malik P; Kiem HP
    PLoS One; 2012; 7(9):e45173. PubMed ID: 23028826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow.
    Kramer BA; Lemckert FA; Alexander IE; Gunning PW; McCowage GB
    J Gene Med; 2006 Sep; 8(9):1071-85. PubMed ID: 16927363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reciprocal relationship between O6-methylguanine-DNA methyltransferase P140K expression level and chemoprotection of hematopoietic stem cells.
    Milsom MD; Jerabek-Willemsen M; Harris CE; Schambach A; Broun E; Bailey J; Jansen M; Schleimer D; Nattamai K; Wilhelm J; Watson A; Geiger H; Margison GP; Moritz T; Baum C; Thomale J; Williams DA
    Cancer Res; 2008 Aug; 68(15):6171-80. PubMed ID: 18676840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging stem cell-derived persistent foci after in vivo selection of lentiviral MGMT-P140K transduced murine bone marrow cells.
    Lin Y; Cheung P; Roth JC; Wilson DL; Gerson SL
    Mol Ther; 2011 Jul; 19(7):1342-52. PubMed ID: 21304493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug selection of mutant methylguanine methyltransferase from different oncoretroviral backbones results in multilineage hematopoietic transgene expression in primary and secondary recipients.
    Davis BM; Reese JS; Lingas K; Gerson SL
    J Hematother Stem Cell Res; 2003 Aug; 12(4):375-87. PubMed ID: 12965075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in vivo drug selection.
    Richard E; Robert E; Cario-André M; Ged C; Géronimi F; Gerson SL; de Verneuil H; Moreau-Gaudry F
    Gene Ther; 2004 Nov; 11(22):1638-47. PubMed ID: 15284838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. F2A sequence linking MGMT(P140K) and MDR1 in a bicistronic lentiviral vector enables efficient chemoprotection of haematopoietic stem cells.
    Maier P; Heckmann D; Spier I; Laufs S; Zucknick M; Allgayer H; Fruehauf S; Zeller WJ; Wenz F
    Cancer Gene Ther; 2012 Nov; 19(11):802-10. PubMed ID: 23037811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT enrichment and second gene co-expression in hematopoietic progenitor cells using separate or dual-gene lentiviral vectors.
    Roth JC; Alberti MO; Ismail M; Lingas KT; Reese JS; Gerson SL
    Virus Res; 2015 Jan; 196():170-80. PubMed ID: 25479595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprotection of human hematopoietic stem cells by simultaneous lentiviral overexpression of multidrug resistance 1 and O(6)-methylguanine-DNA methyltransferase(P140K).
    Maier P; Spier I; Laufs S; Veldwijk MR; Fruehauf S; Wenz F; Zeller WJ
    Gene Ther; 2010 Mar; 17(3):389-99. PubMed ID: 19865182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMT(P140K) into hematopoietic stem cells.
    Jansen M; Sorg UR; Ragg S; Flasshove M; Seeber S; Williams DA; Moritz T
    Cancer Gene Ther; 2002 Sep; 9(9):737-46. PubMed ID: 12189523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.
    Davis BM; Reese JS; Koç ON; Lee K; Schupp JE; Gerson SL
    Cancer Res; 1997 Nov; 57(22):5093-9. PubMed ID: 9371508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablation is not required to select and maintain expression of the drug-resistance gene, mutant MGMT, in primary and secondary recipients.
    Bowman JE; Reese JS; Lingas KT; Gerson SL
    Mol Ther; 2003 Jul; 8(1):42-50. PubMed ID: 12842427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.